World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   249 records for 87 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT02495051
Esophageal Atresia: Metaplasia, Barrett
22/06/2015
Not recruitingNCT02525562
Stryker NTX Registry Scorpio NRG (Re-"Energize"), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert
11/06/2015
RecruitingNCT02367040
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) 12/02/2015
Not recruitingNCT02282176
TINN2: Treat Infection in NeoNates 2
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-003889-14-HUTreat Infections in Neonates 211/12/2014
17/10/2014
RecruitingNCT02236637
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
08/09/2014
RecruitingNCT02156804
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-001286-28-BEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.23/07/2014
AuthorisedEUCTR2014-001286-28-ESA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-NLA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-PTA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/08/2014
AuthorisedEUCTR2014-001286-28-SEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.30/09/2014
AuthorisedEUCTR2014-001286-28-FIA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.17/10/2014
AuthorisedEUCTR2014-001286-28-DKA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.13/08/2014
AuthorisedEUCTR2014-001286-28-ITA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.31/07/2014
AuthorisedEUCTR2014-001286-28-IEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.11/09/2014
AuthorisedEUCTR2014-001286-28-GRA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.08/05/2015
AuthorisedEUCTR2014-001286-28-GBA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody.04/08/2014
AuthorisedEUCTR2014-001286-28-HUA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/12/2014
AuthorisedEUCTR2014-001286-28-ATA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-DEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma after treament with an Anti-CTLA-4 antibody.01/08/2014
RecruitingDRKS00006730A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody08/12/2014
29/05/2014
RecruitingNCT02149108
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-000095-42-SENintedanib (BIBF 1120) vs placebo in refractory colorectal cancer11/08/2014
AuthorisedEUCTR2012-000095-42-BENintedanib (BIBF 1120) vs placebo in refractory colorectal cancer25/08/2014
AuthorisedEUCTR2012-000095-42-NLNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer28/08/2014
AuthorisedEUCTR2012-000095-42-DENintedanib (BIBF 1120) vs placebo in refractory colorectal cancer25/08/2014
AuthorisedEUCTR2012-000095-42-DKNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer21/08/2014
AuthorisedEUCTR2012-000095-42-PLNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer18/11/2014
AuthorisedEUCTR2012-000095-42-PTNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer27/08/2014
AuthorisedEUCTR2012-000095-42-ATNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer13/08/2014
AuthorisedEUCTR2012-000095-42-LUNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer26/06/2014
AuthorisedEUCTR2012-000095-42-FRNintedanib (BIBF 1120) vs placebo in refractory colorectal cancer19/08/2015
26/05/2014
RecruitingNCT02141438
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Recruitment statusMain IDPublic titleDate of registration
RecruitingDRKS00006475Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation04/11/2014
15/05/2014
RecruitingDRKS00006153
QUIPS - Quality improvement in post operative pain treatment
12/05/2014
Not recruitingNCT02227758
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
Recruitment statusMain IDPublic titleDate of registration
RecruitingDRKS00007247Peripheral Nerve Stimulation Registry for Intractable Migraine Headache24/04/2015
16/04/2014
    
1 2 3 4 5 6 7 8 9
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history